Candel therapeutics reports fourth quarter and full year 2024 financial results and recent corporate highlights

Needham, mass., march 13, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the fourth quarter and year ended december 31, 2024, and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking